EBITDA Summary of Bionime Corporation

Bionime Corporation's latest annual EBITDA in 2023 was 179.78 Million TWD , down -52.24% from previous year.
Bionime Corporation's latest quarterly EBITDA in 2024 Q2 was -9.43 Million TWD , down -90.05% from previous quarter.
Bionime Corporation reported an annual EBITDA of 270.36 Million TWD in 2022, up 31.71% from previous year.
Bionime Corporation reported an annual EBITDA of 248.29 Million TWD in 2021, down -4.89% from previous year.
Bionime Corporation reported a quarterly EBITDA of 38.39 Million TWD for 2024 Q1, up 48.53% from previous quarter.
Bionime Corporation reported a quarterly EBITDA of 39.44 Million TWD for 2023 Q3, down -13.87% from previous quarter.

Annual EBITDA Chart of Bionime Corporation (2023 - 2009)

Historical Annual EBITDA of Bionime Corporation (2023 - 2009)

Year	EBITDA	EBITDA Growth
2023	179.78 Million TWD	-52.24%
2022	270.36 Million TWD	31.71%
2021	248.29 Million TWD	-4.89%
2020	216.14 Million TWD	-29.79%
2019	330.84 Million TWD	-0.02%
2018	342.34 Million TWD	-4.49%
2017	357.79 Million TWD	-9.43%
2016	394.33 Million TWD	17.95%
2015	334.31 Million TWD	11.79%
2014	299.06 Million TWD	18.58%
2013	252.21 Million TWD	40.36%
2012	177.14 Million TWD	-38.86%
2011	292.8 Million TWD	42.75%
2010	205.42 Million TWD	10.92%
2009	185.7 Million TWD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-9.43 Million TWD	-90.05%
2024 Q1	38.39 Million TWD	48.53%
2023 Q3	39.44 Million TWD	-13.87%
2023 FY	- TWD	-52.24%
2023 Q1	30.1 Million TWD	-61.3%
2023 Q4	27.91 Million TWD	-29.23%
2023 Q2	45.8 Million TWD	52.16%
2022 Q2	87.97 Million TWD	29.3%
2022 FY	- TWD	31.71%
2022 Q1	68.04 Million TWD	17.16%
2022 Q3	66.16 Million TWD	-24.79%
2022 Q4	77.77 Million TWD	17.54%
2021 Q4	58.07 Million TWD	-4.3%
2021 FY	- TWD	-4.89%
2021 Q1	54.17 Million TWD	-48.62%
2021 Q2	54.79 Million TWD	1.15%
2021 Q3	60.68 Million TWD	10.74%
2020 Q1	39.2 Million TWD	-68.34%
2020 Q2	30.14 Million TWD	-23.1%
2020 Q3	64.64 Million TWD	114.43%
2020 FY	- TWD	-29.79%
2020 Q4	105.44 Million TWD	63.12%
2019 FY	- TWD	-0.02%
2019 Q1	58.8 Million TWD	-54.15%
2019 Q2	97.6 Million TWD	65.98%
2019 Q3	60.79 Million TWD	-37.71%
2019 Q4	123.81 Million TWD	103.65%
2018 FY	- TWD	-4.49%
2018 Q4	128.25 Million TWD	61.97%
2018 Q3	79.18 Million TWD	4.41%
2018 Q2	75.84 Million TWD	26.1%
2018 Q1	60.14 Million TWD	-43.97%
2017 Q4	107.33 Million TWD	6.68%
2017 Q3	100.61 Million TWD	34.62%
2017 FY	- TWD	-9.43%
2017 Q2	74.73 Million TWD	0.39%
2017 Q1	74.45 Million TWD	-42.7%
2016 FY	- TWD	17.95%
2016 Q4	129.92 Million TWD	19.07%
2016 Q3	109.11 Million TWD	19.51%
2016 Q2	91.3 Million TWD	42.68%
2016 Q1	63.99 Million TWD	-34.73%
2015 FY	- TWD	11.79%
2015 Q3	97.01 Million TWD	53.72%
2015 Q4	98.04 Million TWD	1.06%
2015 Q2	63.11 Million TWD	-17.11%
2015 Q1	76.13 Million TWD	-22.81%
2014 Q4	98.63 Million TWD	21.74%
2014 Q1	58.49 Million TWD	-10.08%
2014 Q2	60.9 Million TWD	4.11%
2014 FY	- TWD	18.58%
2014 Q3	81.02 Million TWD	33.04%
2013 Q3	69.51 Million TWD	6.48%
2013 Q1	52.36 Million TWD	37.36%
2013 FY	- TWD	40.36%
2013 Q4	65.05 Million TWD	-6.41%
2013 Q2	65.28 Million TWD	24.67%
2012 Q1	28.79 Million TWD	-69.3%
2012 Q4	38.12 Million TWD	-41.07%
2012 Q3	64.69 Million TWD	43.23%
2012 Q2	45.16 Million TWD	56.84%
2012 FY	- TWD	-38.86%
2011 Q1	64.13 Million TWD	0.22%
2011 FY	- TWD	42.75%
2011 Q4	93.79 Million TWD	36.1%
2011 Q3	68.91 Million TWD	2.79%
2011 Q2	67.04 Million TWD	4.53%
2010 Q4	63.99 Million TWD	13.18%
2010 Q2	50.85 Million TWD	47.5%
2010 Q3	56.53 Million TWD	11.18%
2010 Q1	34.47 Million TWD	0.0%
2010 FY	- TWD	10.92%
2009 FY	- TWD	0.0%

Peer EBITDA Comparison of Bionime Corporation

Name	EBITDA	EBITDA Difference
Nang Kuang Pharmaceutical Co., Ltd.	402.69 Million TWD	55.356%
Maxigen Biotech Inc.	177.09 Million TWD	-1.518%
SciVision Biotech Inc.	281.34 Million TWD	36.1%
Pegavision Corporation	2.91 Billion TWD	93.839%
Visco Vision Inc.	733.58 Million TWD	75.493%

Global Stocks Search

Bionime Corporation (4737.TW)

EBITDA Summary of Bionime Corporation

Annual EBITDA Chart of Bionime Corporation (2023 - 2009)

Historical Annual EBITDA of Bionime Corporation (2023 - 2009)

Peer EBITDA Comparison of Bionime Corporation